Source: [pubmed](https://pubmed.ncbi.nlm.nih.gov/42177552/)
Authors: Zou F, Wu Z, Wang S, Xu M, Xia P
Venue: J Transl Med · 2026 May 23
AI relevance (5/5): Directly addresses barrier dysfunction via epithelial pyroptosis, microbiota-host signalling (butyrate-AhR axis), and DSS colitis model.
The gut microbiome produces a short-chain fatty acid called butyrate, which is well-known for keeping the intestinal lining healthy, but the precise molecular steps involved have remained unclear. This animal study investigated whether butyrate protects the colon by suppressing a specific form of inflammatory cell death called pyroptosis—a process in which colonic epithelial cells rupture and release signals that amplify gut inflammation. The researchers used a dextran sodium sulfate (DSS) mouse model, a standard preclinical system for mimicking the features of ulcerative colitis, to test this idea. They found that butyrate engages a receptor protein called the aryl hydrocarbon receptor (AhR) inside epithelial cells, and that this interaction dials down the pyroptosis machinery in those cells. When AhR signalling was blocked experimentally, butyrate lost its ability to protect the gut lining, confirming the pathway's necessity. The study positions the butyrate–AhR axis as a mechanistically specific link between microbiome metabolism and mucosal barrier defence. Because both butyrate production and AhR signalling can be influenced by diet and microbial community composition, these findings may eventually inform nutritional or microbiome-targeted strategies for inflammatory bowel disease, though significant translational steps remain.
This is a preclinical in vivo study using a DSS-induced acute colitis mouse model, the field's most widely employed chemical-injury proxy for ulcerative colitis. Mice received butyrate supplementation (route and dose reported in the full paper) alongside DSS exposure, with additional cohorts receiving AhR pathway inhibitors to dissect mechanistic necessity. Endpoints included macroscopic disease activity, colon histopathology, Western blot and immunofluorescence quantification of pyroptosis markers (caspase-1, GSDMD), and inflammatory cytokine profiling; in vitro epithelial cell experiments likely complemented the in vivo work. Sample sizes and intervention durations are as reported in the primary article; full numerical details require access to the complete manuscript.
As an animal study using a chemical-injury colitis model, findings cannot be directly extrapolated to human inflammatory bowel disease, where genetic heterogeneity, disease chronicity, and a far more complex microbiome all modulate outcomes. The DSS model recapitulates acute mucosal injury but does not fully replicate the relapsing–remitting or fibrotic features of Crohn's disease or chronic ulcerative colitis. It remains unknown whether endogenous butyrate concentrations achievable through diet or microbiome modulation in humans are sufficient to activate AhR at therapeutically meaningful levels in inflamed mucosa. The next critical experiments would include human colonoid (organoid) validation of the butyrate–AhR–pyroptosis axis, assessment in germ-free or antibiotic-depleted mouse models to confirm microbiota dependence, and dose–response characterisation bridging rodent pharmacology to clinically relevant exposures.
This study mechanistically extends the broader microbiota-mucosal protection theme represented across the corpus: it directly parallels [§119], which also investigates epithelial pyroptosis as a central driver of colitis pathogenesis but targets the ZBP1 pathway rather than the butyrate–AhR axis, together suggesting that converging anti-pyroptotic strategies may each offer distinct therapeutic entry points. It parallels [§120], in which Eubacterium rectale-derived glutamine metabolites attenuate DSS colitis via GLS2/NF-κB signalling, underscoring a growing pattern wherein specific microbial metabolites engage discrete receptor-level mechanisms to limit mucosal inflammation. The study also parallels [§118], which demonstrates that a plant-derived mannan modulates gut microbiota and inflammation in the same DSS model through a microbiota-remodelling rather than direct metabolite-receptor route, highlighting how different upstream strategies converge on colitis mitigation. Collectively, these articles build a multi-pathway map of microbiome–epithelium crosstalk in which the butyrate–AhR findings reported here occupy a newly specified mechanistic node linking microbial fermentation products to programmed epithelial cell death.
